511 related articles for article (PubMed ID: 22298121)
1. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study.
Ibrahim L; Diazgranados N; Franco-Chaves J; Brutsche N; Henter ID; Kronstein P; Moaddel R; Wainer I; Luckenbaugh DA; Manji HK; Zarate CA
Neuropsychopharmacology; 2012 May; 37(6):1526-33. PubMed ID: 22298121
[TBL] [Abstract][Full Text] [Related]
2. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.
Mathew SJ; Murrough JW; aan het Rot M; Collins KA; Reich DL; Charney DS
Int J Neuropsychopharmacol; 2010 Feb; 13(1):71-82. PubMed ID: 19288975
[TBL] [Abstract][Full Text] [Related]
3. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
[TBL] [Abstract][Full Text] [Related]
5. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Diazgranados N; Ibrahim L; Brutsche NE; Newberg A; Kronstein P; Khalife S; Kammerer WA; Quezado Z; Luckenbaugh DA; Salvadore G; Machado-Vieira R; Manji HK; Zarate CA
Arch Gen Psychiatry; 2010 Aug; 67(8):793-802. PubMed ID: 20679587
[TBL] [Abstract][Full Text] [Related]
6. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Zarate CA; Brutsche NE; Ibrahim L; Franco-Chaves J; Diazgranados N; Cravchik A; Selter J; Marquardt CA; Liberty V; Luckenbaugh DA
Biol Psychiatry; 2012 Jun; 71(11):939-46. PubMed ID: 22297150
[TBL] [Abstract][Full Text] [Related]
7. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.
Luckenbaugh DA; Ibrahim L; Brutsche N; Franco-Chaves J; Mathews D; Marquardt CA; Cassarly C; Zarate CA
Bipolar Disord; 2012 Dec; 14(8):880-7. PubMed ID: 22978511
[TBL] [Abstract][Full Text] [Related]
8. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
[TBL] [Abstract][Full Text] [Related]
10. Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial.
Costi S; Soleimani L; Glasgow A; Brallier J; Spivack J; Schwartz J; Levitch CF; Richards S; Hoch M; Stade EC; Welch A; Collins KA; Feder A; Iosifescu DV; Charney DS; Murrough JW
Neuropsychopharmacology; 2019 Sep; 44(10):1812-1819. PubMed ID: 30858518
[TBL] [Abstract][Full Text] [Related]
11. Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans.
Zhuo C; Tian H; Li G; Chen M; Jiang D; Lin X; Xu Y; Wang W
Brain Behav; 2019 Nov; 9(11):e01423. PubMed ID: 31617335
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of intranasal ketamine in major depressive disorder.
Lapidus KA; Levitch CF; Perez AM; Brallier JW; Parides MK; Soleimani L; Feder A; Iosifescu DV; Charney DS; Murrough JW
Biol Psychiatry; 2014 Dec; 76(12):970-6. PubMed ID: 24821196
[TBL] [Abstract][Full Text] [Related]
13. Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
Gilbert JR; Yarrington JS; Wills KE; Nugent AC; Zarate CA
Int J Neuropsychopharmacol; 2018 Aug; 21(8):740-747. PubMed ID: 29668918
[TBL] [Abstract][Full Text] [Related]
14. A Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression.
Park LT; Lener MS; Hopkins M; Iadorola N; Machado-Vieira R; Ballard E; Nugent A; Zarate CA
J Clin Psychopharmacol; 2017 Jun; 37(3):355-358. PubMed ID: 28338546
[TBL] [Abstract][Full Text] [Related]
15. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Fava M; Freeman MP; Flynn M; Judge H; Hoeppner BB; Cusin C; Ionescu DF; Mathew SJ; Chang LC; Iosifescu DV; Murrough J; Debattista C; Schatzberg AF; Trivedi MH; Jha MK; Sanacora G; Wilkinson ST; Papakostas GI
Mol Psychiatry; 2020 Jul; 25(7):1592-1603. PubMed ID: 30283029
[TBL] [Abstract][Full Text] [Related]
16. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Duncan WC; Sarasso S; Ferrarelli F; Selter J; Riedner BA; Hejazi NS; Yuan P; Brutsche N; Manji HK; Tononi G; Zarate CA
Int J Neuropsychopharmacol; 2013 Mar; 16(2):301-11. PubMed ID: 22676966
[TBL] [Abstract][Full Text] [Related]
17. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.
Downey D; Dutta A; McKie S; Dawson GR; Dourish CT; Craig K; Smith MA; McCarthy DJ; Harmer CJ; Goodwin GM; Williams S; Deakin JF
Eur Neuropsychopharmacol; 2016 Jun; 26(6):994-1003. PubMed ID: 27133029
[TBL] [Abstract][Full Text] [Related]
18. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA
J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782
[TBL] [Abstract][Full Text] [Related]
19. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.
Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G
Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836
[TBL] [Abstract][Full Text] [Related]
20. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
Preskorn SH; Baker B; Kolluri S; Menniti FS; Krams M; Landen JW
J Clin Psychopharmacol; 2008 Dec; 28(6):631-7. PubMed ID: 19011431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
